Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

First Posted Date
2015-10-12
Last Posted Date
2020-07-21
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
63
Registration Number
NCT02573870
Locations
🇺🇸

GSK Investigational Site, McKinney, Texas, United States

Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma

First Posted Date
2015-10-02
Last Posted Date
2021-05-06
Lead Sponsor
Seton Healthcare Family
Target Recruit Count
118
Registration Number
NCT02566902
Locations
🇺🇸

Dell Children's Medical Center, Emergency Department, Austin, Texas, United States

Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy

First Posted Date
2015-09-16
Last Posted Date
2016-03-15
Lead Sponsor
University of Copenhagen
Target Recruit Count
42
Registration Number
NCT02551276

The Effects of RPL554 on Top of Standard COPD Reliever Medications

First Posted Date
2015-09-04
Last Posted Date
2016-09-09
Lead Sponsor
Verona Pharma plc
Target Recruit Count
36
Registration Number
NCT02542254
Locations
🇬🇧

Medicines Evaluation Unit, Manchester, United Kingdom

Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2015-08-14
Last Posted Date
2018-05-02
Lead Sponsor
University of Sao Paulo General Hospital
Target Recruit Count
27
Registration Number
NCT02523833
Locations
🇧🇷

Olívia Meira Dias, São Paulo, Brazil

Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma

First Posted Date
2015-07-20
Last Posted Date
2017-11-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
60
Registration Number
NCT02502734
Locations
🇩🇰

GSK Investigational Site, Randers, Denmark

Repeat Emergency Department Visits Among Patients With Asthma and COPD

First Posted Date
2015-07-16
Last Posted Date
2019-06-04
Lead Sponsor
State University of New York at Buffalo
Target Recruit Count
6
Registration Number
NCT02499887
Locations
🇺🇸

Erie County Medical Center, Buffalo, New York, United States

Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-04-27
Last Posted Date
2016-09-09
Lead Sponsor
Verona Pharma plc
Target Recruit Count
29
Registration Number
NCT02427165
Locations
🇸🇪

Skane University Hospital, Lund, Sweden

🇬🇧

Celerion, Belfast, United Kingdom

Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-04-01
Last Posted Date
2016-09-20
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
14
Registration Number
NCT02405598
Locations
🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

© Copyright 2024. All Rights Reserved by MedPath